The Rheumatoid Arthritis Diagnostic Tests Market Size is valued at USD 2.03 billion in 2023 and is predicted to reach USD 3.19 billion by the year 2031 at a 6.05% CAGR during the forecast period for 2024-2031.
Rheumatoid arthritis (RA) is diagnosed with the help of a combination of blood tests, imaging, and physical examination. A thorough physical examination of the joints for swelling and tenderness is also crucial. These tests together help confirm the diagnosis and determine the severity of RA.
By facilitating a fast diagnosis and the start of the right course of therapy, these tests help patients get better results. The accuracy and specificity of RA diagnostics are being improved by developments in diagnostic technology, including biomarker detection and DNA testing techniques, producing more dependable outcomes. The advantages of early recognition and illness surveillance are becoming more widely known to individuals and physicians, which is driving market expansion. The demand for RA diagnostic tests is growing as a result of proactive measures taken by government departments and medical institutions to expand the availability of testing services as well as enhance the quality of medical facilities.
However, the intricacy and diversity of illness appearance are the main obstacles facing manufacturers for RA diagnostic testing. A diverse range of medical signs and illness pathways describe rheumatoid arthritis, an inflammatory illness. Because of this heterogeneity, it can be difficult for doctors to diagnose RA correctly, particularly in the beginning phases when indications can mimic those of other autoimmune or rheumatic diseases. The method of diagnosis is made more difficult by the absence of particular diagnostics that differentiate RA from other types of rheumatism.
Furthermore, Regional regulatory systems are complicated and ever-changing, necessitating thorough documentation and strict adherence to standards. Delays in product launches and market entrance are common results of the time and money needed to meet these standards. Rising negative reimbursement circumstances and ongoing modifications to government regulations are among the primary challenges limiting industry expansion.
Competitive Landscape
Some Major Key Players In The Rheumatoid Arthritis Diagnostic Tests Market:
- Abbott Laboratories Inc.
- Siemens Healthineers AG
- Thermo Fisher Scientific Inc.
- Exagen Inc.
- Augurex Life Sciences Corp.
- Danaher Corporation
- Bio-Rad Laboratories, Inc.
- Tulip Diagnostics (P) Ltd
- Boditech Med Inc.
- Labcorp,
- Antibodies Inc.,
- Beckman Coulter, Inc.,
- Euro Diagnostica AB,
- Hoffmann-La Roche Ltd.,
- Qiagen NV,
- Specialty Networks, LLC
- Genway Biotech, Inc.,
- Microdrop LLC (imaware)
- Svar Life Science AB,
- Other Market Players
Market Segmentation:
The rheumatoid arthritis diagnostic tests market is segmented based on test type and end user. Based on test type category, the market is segmented into serology tests and monitoring RA treatment efficiency tests. This test type segment is further divided into different sub segments like Serology Test (Erythrocyte Sedimentation Rate (ESR), Rheumatoid Factor (RF), Anti-cyclic Citrullinated Peptide (anti-CCP), Antinuclear Antibody (ANA), Uric Acid, Other Tests), Monitoring RA Treatment Efficiency Tests (Salicylate Level Count, Muscle Enzyme Tests (CPK, Aldolase), Creatinine Test). By end user, the market is segmented into diagnostic laboratories, private laboratories, public laboratories, and ambulatory surgical centers.
Based On The End-User, The Diagnostic Laboratories Is Accounted As A Major Contributor To The Rheumatoid Arthritis Diagnostic Tests Market
The diagnostic laboratories' rheumatoid arthritis diagnostic tests market is anticipated to lead with a significant global market share. Owing to their sophisticated facilities and proficiency in carrying out a broad array of diagnostic examinations crucial for the identification and treatment of RA. Modern equipment, robotic procedures, and specialist staff skilled in carrying out the biological diagnostics, radiographic analyses, and serology tests required for Rheumatoid diagnostics are often found in these laboratories.
Serology Test Segment To Witness Growth At A Rapid Rate.
Serology tests are currently the dominant method because they play a fundamental role in diagnosing and monitoring rheumatoid arthritis (RA). These tests primarily identify antibodies, such as rheumatoid factor (RF) and anti-CCP (anti-cyclic citrullinated peptide) antibodies, that are important biomarkers linked to rheumatoid arthritis (RA).
In The Region, The North American Rheumatoid Arthritis Diagnostic Tests Market Holds A Significant Revenue Share.
The North American rheumatoid arthritis diagnostic tests market is expected to register the prominent market share in revenue in the near future. It can be attributed to increasing supportive government policies and a robust diagnostic system. In addition, Asia Pacific is likely to grow rapidly in the global rheumatoid arthritis diagnostic tests market because of the improvement of healthcare facilities and the increasing presence of many target groups in this region.
Recent Developments:
- In January 2023, Helix and QIAGEN N.V., a prominent provider of Sample to Insight solutions, have formed a global strategic agreement to collaborate on the development of companion diagnostics for genetic disorders. As part of the agreement, Helix will utilize the Helix® Laboratory Platform to provide companion diagnoses in the United States, while QIAGEN will employ the QIASeq Human Exome Kits in the rest of the world.
- In Apr 2022, United Rheumatology, LLC was acquired by Specialty Networks, LLC. specialist Networks, which is present in the fields of urology, gastroenterology, and rheumatology, provides a comprehensive solution that significantly benefits independent specialist providers as well as clients in the business.
Rheumatoid Arthritis Diagnostic Tests Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 2.03 Bn |
|
Revenue Forecast In 2031 |
USD 3.19 Bn |
|
Growth Rate CAGR |
CAGR of 6.05% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type and End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Abbott Laboratories Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Exagen Inc., Augurex Life Sciences Corp., Danaher Corporation, Bio-Rad Laboratories, Inc., Tulip Diagnostics (P) Ltd, Boditech Med Inc., and Other Market Players |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
